Israel Defense Forces Medical Corps, Ramat Gan, Israel.
Department of Urology, Rabin Medical Center, Petah Tikva, Israel.
Eur Urol Focus. 2021 May;7(3):508-512. doi: 10.1016/j.euf.2021.04.022. Epub 2021 May 11.
Prostate cancer and metabolic syndrome are common among men in the Western world. As the population grows older and life expectancy increases, the rates of both diseases are expected to increase. We now recognize that metabolic syndrome and prostate cancer interact. Metabolic syndrome may be a risk factor for prostate cancer and may also worsen outcomes. At the same time, treatment for prostate cancer may exacerbate metabolic syndrome and cardiac disease. This mini-review summarizes current evidence and puts it into clinical prospective. PATIENT SUMMARY: Metabolic syndrome is now a global epidemic. It is characterized by obesity, insulin resistance, high blood pressure, and high blood lipids. There is a complex interaction between metabolic syndrome and the risk of prostate cancer, as treatment of one disease may affect the other.
前列腺癌和代谢综合征在西方世界的男性中很常见。随着人口老龄化和预期寿命的延长，这两种疾病的发病率预计都将上升。我们现在认识到代谢综合征和前列腺癌相互作用。代谢综合征可能是前列腺癌的一个危险因素，也可能使预后恶化。与此同时，前列腺癌的治疗可能会使代谢综合征和心脏病恶化。这篇迷你综述总结了目前的证据，并将其置于临床前望中。患者总结：代谢综合征现在是一种全球性的流行疾病。其特征为肥胖、胰岛素抵抗、高血压和高血脂。代谢综合征和前列腺癌的风险之间存在着复杂的相互作用，因为一种疾病的治疗可能会影响另一种疾病。
